Medulloblastoma predominantly affects children. About 70% of cases occur in patients under 15 years old, with an incidence of 5 cases per million, and an incidence’s peak at 5 years of age. In post-pubertal and adult patients, however, the incidence is about 0.6 cases per million, translating into 450 post-pubertal and adult cases annually in Europe. Predominantly young adults are affected.
Post-pubertal patients all bear an intermediate to high prognostic risk, leading to death and disability in a large part of patients. While treatment has been step-wise developed for children, it has never been optimized for post-pubertal patients in a prospective, randomized way. As such, the most effective treatment with the lowest possible rate of side effects is still unknown in this age group.
Considering the high and uncovered medical and scientific need for research on medulloblastoma in post-pubertal and adult patients, the PersoMed-I consortium initiated the randomized Phase II EORTC 1634 trial with integrated scientific subprojects to better understand medulloblastoma in these age groups.
The EORTC 1634 study trail provides a unique opportunity to investigate highly relevant toxicity and efficacy aspects in a highly under-investigated population with an eminent output for affected patients, clinical and translational research, and society alike.
To find out more on the project or how to support us please contact email us at firstname.lastname@example.org